Scott A. Biller
Member of Scientific Advisory BoardDr. Scott A. Biller, Ph.D., serves as Non-Executive Director of OMass Therapeutics Limited since April 28, 2022. Dr. Biller serves as a Board Observer at Gate Bioscience, Inc. He serves as Executive Venture Partner of GV Management Company, LLC. He is Member of Scientific Advisory Board at Vividion Therapeutics, Inc. since September 2021. He serves as Board of Directors for OMass Therapeutics. He serves as Director at ROME Therapeutics, Inc. since February 2021. Dr. Biller served as Member of Scientific Advisory Board at Agios Pharmaceuticals, Inc. since 2021. He serves as an Independent Director of Foghorn Therapeutics Inc. since January 2020. Dr. Biller is also the sole proprietor of Biller Consulting. Dr. Biller served as the Chief Scientific Officer of Agios Pharmaceuticals, Inc. since September 2010 until December 31, 2019 and served as its Strategic Advisor since December 31, 2019. In Agios Pharmaceuticals, Inc., during his tenure as CSO, he advanced seven molecules into the clinic, leading to two marketed therapies and multiple late-stage candidates. He has also held leadership positions at Novartis Pharmaceuticals and Bristol Myers Squibb. Dr. Biller joined Agios from Novartis Pharmaceuticals, where he served as Vice President and Head of Global Discovery Chemistry at the Novartis Institutes for BioMedical Research from 2003 to 2010. He is biotech advisor and Board member. During his career, Dr. Biller led the efforts to discover multiple approved products, including TIBSOVO® and IDHIFA®, for acute myeloid leukemia harboring IDH1 and IDH2 mutations, respectively, the DPP4 inhibitor ONGLYZA® for type 2 diabetes and the SGLT2 inhibitor FARXIGA® for type 2 diabetes and the MTP inhibitor JUXTAPID® for familial hypercholesterolemia. He has extensive drug discovery and development experience. At Novartis, he was responsible for the worldwide discovery chemistry functions at NIBR, including medicinal, combinatorial and computational chemistry, as well as the research metabolism and pharmacokinetics group. Prior to joining NIBR, he served as Vice President of Pharmaceutical Candidate Optimization at the Bristol-Myers Squibb (BMS) Pharmaceutical Research Institute and Executive Director of Drug Discovery chemistry for the BMS research site in Lawrenceville, New Jersey. His work focused on the identification of superior drug candidates through the optimization of the physicochemical, ADME and safety attributes of molecules, in parallel with efficacy, in order to increase success rates from drug candidate nomination to launch. He served as the Head of Discovery Chemistry for the BMS Pharmaceutical Research Institute's Lawrenceville site, responsible for overseeing chemistry for oncology, immunology, inflammation, pulmonary diseases and cardiovascular diseases. He served as an Executive Director of Metabolic Diseases Chemistry, with responsibility for medicinal chemistry programs in hypercholesterolemia and atherosclerosis, diabetes, obesity, osteoporosis and the endocrine dysfunction of the aging population. He contributed to robust pipelines at both BMS and Novartis, culminating in one medicine launched worldwide (Onglyza for the treatment of Type 2 diabetes) and three additional drugs reaching Phase 3 clinical development. He served as Member of Scientific Advisory Board at Denali Therapeutics Inc. He serves as a Member of Scientific Advisory Board at Arbutus Biopharma Corporation. He has been a Member of Scientific Advisory Board at Syros Pharmaceuticals, Inc. since April 2013. He serves as Independent Director of Remix Therapeutics Inc. since June 2020. He served as Member of Scientific Advisory Board at Arvinas, Inc. since February 11, 2014. He serves as a Member of Scientific Advisory Board at Envoy Therapeutics, Inc. During his career, Dr. Biller contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are in pivotal trials. He has over 80 scientific papers and issued patents. He completed his BS degree in Chemistry at the Massachusetts Institute of Technology in 1976 where he did his undergraduate research. Dr. Biller was awarded NIH Postdoctoral Fellowship from 1982 to 1983 in natural product synthesis at Columbia University. In 1982, he completed his Ph.D. in Organic Chemistry at the California Institute of Technology (Caltech).
Positions
- Company NameSyros Pharmaceuticals, Inc.Stock CodeSYRSPositionMember of Scientific Advisory BoardColleagues
